
    <html>
    <head><title>ACB.TO</title>
<style>
body {
  font-family: Arial, sans-serif;
  margin: 20px;
}
.container {
  display: grid;
  grid-template-columns: 50% 50%;
  grid-template-rows: auto auto;
  gap: 20px;
}
img {
  width: 100%;
  height: auto;
  max-height: 400px;
  border: 1px solid #ccc;
  object-fit: contain;
}

.cell {
  padding: 10px;
}
.table-scroll {
  max-height: 400px;
  overflow-y: auto;
  border: 1px solid #aaa;
}
table {
  width: 100%;
  border-collapse: collapse;
}
th, td {
  border: 1px solid #aaa;
  padding: 5px;
  text-align: left;
  font-size: 14px;
}
.negative {
  background: linear-gradient(to right, #ffdddd, white);
}
.positive {
  background: linear-gradient(to right, white, #ddffdd);
}
.pos-light  { background: #e6ffe6; }  
.pos-mid    { background: #99ff99; }  
.pos-strong { background: #33cc33; }   

.neg-light  { background: #ffe6e6; }   
.neg-mid    { background: #ff9999; }   
.neg-strong { background: #ff3333; }   

h2 { border-bottom: 2px solid #444; }
<script>
function toggleText(id) {
  const moreText = document.getElementById(id);
  const btn = document.getElementById(id + "_btn");

  if (moreText.style.display === "none") {
    moreText.style.display = "inline";
    btn.innerText = " Show less";
  } else {
    moreText.style.display = "none";
    btn.innerText = " Show more";
  }
}
</script>
</style>
</head>
    <body>
    <h2><span style='color:#1e66f5; font-weight:900; margin-right:10px;'>quarterly earnings d</span> ACB.TO  <span style='color:orange; font-weight:800; margin-left:8px;'>nan</span>
        <span style='font-weight:normal; font-size: 18px;'>(14d - reverse stock split)</span>
        <span style='color:black; font-weight:bold; font-size: 20px;'> </span>
        <a href='https://finance.yahoo.com/chart/ACB.TO?interval=1mo' target='_blank'>Yahoo</a>
        <span style='font-weight:600;'>  — </span>
    </h2>

    <div class="container">
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><div class='table-scroll'><table><tr><th>Date</th><th>Score</th><th>AMR</th><th>Type</th><th>Summary</th><th>Links</th></tr><tr class='neg-light'><td>2025-09-05</td><td>-0.20</td><td></td><td>analyst meetings</td><td>-0.2 local feel              __   ACB.TO __    -> i:0.2<-                      <br><br>FEELING: total score -0.2 Reasoning: The news primarily focuses on a downgrade from Seaport Global affecting Hexo and Canopy Growth, with Aurora Cannabis (ACB) remaining neutral. While not a direct downgrade of ACB, the overall sentiment is negative due to anticipated price drops and margin compression across the Canadian cannabis sector. This indicates potential headwinds for ACB as well, even if it's currently rated neutrally. Here's a breakdown of the contributing factors: Analyst meetings (-0.1): A downgrade from a major institution (Seaport Global) negatively impacts sentiment. sector headwinds (-0.1): The news highlights broader issues (increased supply, price drops, margin compression) affecting the entire Canadian cannabis sector, which will likely impact ACB. The news does not contain any positive catalysts like FDA approvals, accretive acquisitions, or positive guidance updates. The focus on potential price drops and margin compression creates a cautious outlook, justifying a slightly negative score. --- <br> - Canadian cannabis stocks face headwinds with Seaport Global downgrading Hexo and Canopy Growth to neutral due to anticipated price drops and margin compression driven by increased supply. Investors should proceed with caution. <br><br>*** REZUMAT *** - Seaport Global downgraded Hexo (HEXO) and Canopy Growth (CGC) to neutral. - Aurora Cannabis (ACB) and Tilray (TLRY) remain neutral. - Aphria (APHA) maintains a buy rating. - Green Organic Dutchman (TGODF) rating pending funding news. - Expect price and margin drops due to supply exceeding retail. - Hexo down 5.53% to $2.39; Canopy Growth down 2.37% to $18.97. - Tilray shares up 0.72%.   (gemma3:12b-it-q4_K_M on 2025-09-06 12:40:27)</td><td><a href='https://www.thestreet.com/investing/hexo-and-canopy-growth-tumble-as-seaport-global-expects-pot-prices-to-drop-15125300' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-09-04</td><td>-0.20</td><td></td><td>Analyst meetings</td><td>-0.2 local feel              __   ACB.TO __    -> i:0.2<-                      <br><br>FEELING: total score -0.2 Reasoning: The news primarily focuses on the performance of the Global Cannabis Stock Index and related ETFs (MSOS). While it mentions ACB (Aurora Cannabis) specifically, the information is largely descriptive of broader market trends and doesn's offer any specific, forward-looking information about ACB's performance or strategy. Here's a breakdown of the contributing factors: Global Cannabis Stock Index downturn: This indicates a negative sentiment for the entire sector, impacting ACB as part of that index (-0.1). ACB's YTD performance: ACB is down 15.4% YTD. This is a negative data point, but it's backward-looking and doesn't provide insight into future prospects (-0.1). General caution/defensive portfolio strategy: This suggests a negative outlook for cannabis stocks in general, which would affect ACB (-0.05). The article doesn't mention any of the key events listed (quarterly results, dividends, acquisitions, management changes, guidance, lawsuits, FDA decisions, etc.). It's largely a commentary on past performance and a warning about potential risks, which receive low scores. --- <br> - The Global Cannabis Stock Index experienced a significant downturn after a strong August. Several stocks appear overvalued or face challenges, warranting caution. Investors should be aware of potential downside risks and consider a more defensive portfolio strategy. <br><br>*** REZUMAT *** - Global Cannabis Stock Index dropped 9.7% in two days, reversing gains from August. - MSOS ETF is down 17.2% since end-August, up 21.0% YTD. - Index is up only 1.6% YTD after a 45.5% jump in August. - 23 stocks in the index are up 39.2% quarter-to-date. - Aurora Cannabis (ACB) is down 15.4% YTD and not on the Focus List. - Canopy Growth (CGC) is down 49.1% YTD and projected to hit a new low. - Glass House Brands (GLASF) is up 21.7% YTD, but considered overvalued. - SNDL (SNDL) is up 40.5% YTD, owns "bad" MSOs. - Tilray Brands (TLRY) is down 10.9% YTD, considered expensive. - Trulieve (TCNNF) is up 44.7% YTD, margins may be unsustainable. - Village Farms (VFF) is up 234.6% YTD, considered overvalued.   (gemma3:12b-it-q4_K_M on 2025-09-05 11:35:47)</td><td><a href='https://www.newcannabisventures.com/these-cannabis-stocks-are-at-risk-of-falling-substantially/' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-09-03</td><td>-0.35</td><td></td><td>quarterly earnings</td><td>-0.35 local feel              __   ACB.TO __    -> i:0.35<-                      <br><br>FEELING: total score -0.35 Breakdown: quarterly or annual results (disappointing): -0.3 (Significant negative impact due to anticipated disappointing results and delayed profitability) analyst meetings (negative outlook from MKM Partners): -0.05 (Analysts' downgrades receive a low score, but the consistent negative outlook reinforces the disappointing results) The rest of the news contains backward-looking data and promotional language, so it receives a very low absolute score value. --- <br> - Cannabis stocks are facing headwinds with anticipated disappointing quarterly results. MKM Partners predicts slower sales growth, increased costs, and delayed profitability for key players like Canopy Growth and Aurora Cannabis. Investors should proceed with caution. <br><br>*** REZUMAT *** - MKM Partners expects disappointing quarterly results for cannabis companies. - Next quarter won't show meaningful sales acceleration. - Aurora Cannabis: Buying trends slowed in July/August. - Canopy Growth: Profitability expected in Q1 2021, delayed from 2020 consensus. - Tilray: EBITDA positive expected in Q1 2022, later than consensus. - Hexo: EBITDA positive consensus matches MKM’s estimate. - Canadian cannabis market: Pricing down, consumption contracting.   (gemma3:12b-it-q4_K_M on 2025-09-04 03:31:18)</td><td><a href='https://www.thestreet.com/investing/canopy-aurora-caught-up-in-bearish-mkm-partners-note-15112717' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-09-03</td><td>-0.30</td><td>14</td><td>reverse stock split</td><td>-0.3 local feel              __   ACB.TO __    -> i:0.5<-                     **   ** 2025-09-26 **   <br><br>** 2025-09-26  reverse stock split ***<br>FEELING: total score -0.3 Here's a breakdown of the scoring: Share consolidations (reverse splits): -0.3 (The proposed reverse stock split, ranging from 5-for-1 to 15-for-1, is a significant negative signal. It's typically a measure taken to avoid delisting and indicates financial distress. The range adds to the uncertainty.) Management changes: 0 (While there's mention of a new CEO and scaled-down compensation, this isn't presented as overwhelmingly positive or negative. It's a neutral change.) quarterly or annual results: 0.1 (Canada adult-use revenue increased by 43% year-over-year. This is a positive, but the backward-looking nature of the data limits the score.) Yahoo Finance rating: -0.1 (Hold consensus rating is a neutral to slightly negative signal.) The other points mentioned (proxy vote, U.S. market positioning, ISS recommendation) are either procedural or don't carry significant financial implications on their own. --- <br> - Canopy Growth's proxy vote is a crucial step towards stabilizing finances and advancing U.S. market entry. Shareholder approval of the reverse stock split and governance proposals is vital for the company's long-term value creation, though risks remain in the volatile cannabis sector. <br><br>*** REZUMAT *** - Upcoming shareholder meeting: September 26, 2025, to vote on directors, auditors, reverse split, and executive pay. - Board endorsement: Proposals backed by the board and ISS to align governance with strategy. - Board refreshment: Electing 5 directors, including Joe Bayern (Aurora Cannabis), aiming for 80% independent directors. - Executive compensation: New CEO Luc Mongeau's package scaled down compared to predecessor. - STI payout: 77.6% of target achieved, linked to 17.6% EBITDA and 29.3% revenue targets. - Reverse stock split: Proposed 5-for-1 to 15-for-1 ratio to meet exchange requirements and avoid delisting. - U.S. market positioning: Stakes in Acreage Holdings and Wana Wellness via Canopy USA, LLC. - Quorum requirement: 33 1/3% of outstanding shares needed to avoid adjournment costs. - ISS recommendation: Recommends voting FOR all proposals. - Yahoo Finance rating: Hold consensus, projecting narrowing losses by FY 2026. - Q1 FY 2026 results: Canada adult-use revenue increased by 43% year-over-year.   (gemma3:12b-it-q4_K_M on 2025-09-04 07:29:58)</td><td><a href='https://www.ainvest.com/news/canopy-growth-proxy-vote-endorsement-strategic-catalyst-shareholder-market-positioning-2509/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-02</td><td>0.30</td><td></td><td>major political actions</td><td>0.3 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: The news primarily revolves around a potential Biden win and state-level legalization votes (New Jersey & Arizona). This falls under "regulatory changes" and has a positive outlook for the cannabis sector. Regulatory Changes (Beneficial): +0.2 (Legalization in New Jersey and Arizona is a positive regulatory development, opening up new markets and potentially boosting revenue for companies like ACB.) Potential Biden Win: +0.1 (A Biden win is generally perceived as more favorable for cannabis reform, although the extent of impact remains to be seen. This contributes a small positive effect.) The rally in ACB's stock price (12.53%) is a direct consequence of these developments, reinforcing the positive sentiment. The news is forward-looking, focusing on potential future impacts. --- <br> - Cannabis stocks rallied on potential Biden win and New Jersey/Arizona legalization votes. Investors should monitor election results and regulatory developments closely as they impact the sector's growth prospects. <br><br>*** REZUMAT *** - ACB jumped 12.53% to $4.99 on potential Biden win. - CGC rose 4.53% to $19.86. - TLRY gained 12.92% to $6.78. - Biden needs 270 Electoral College votes; currently has 264. - Trump has 214 Electoral College votes. - New Jersey and Arizona legalized recreational marijuana. - New Jersey is the largest East Coast state to legalize. - Arizona approved legalization after a failed 2016 proposal.   (gemma3:12b-it-q4_K_M on 2025-09-04 12:41:51)</td><td><a href='https://www.thestreet.com/investing/aurora-cannabis-canopy-growth-joe-biden-president' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-02</td><td>0.35</td><td></td><td>nan</td><td>0.35 local feel              __   ACB.TO __    -> i:0.35<-                      <br><br>FEELING: total score 0.35 Here's a breakdown of the scoring: quarterly or annual results: Loss per share estimate improved 1 cent for 2025 (+0.1). This indicates a slight positive revision to future earnings. strategic partnerships or joint ventures: The mention of Village Farms and Aurora Cannabis' international sales, while not direct partnerships with ACB.TO, suggests a positive trend in the broader cannabis market, which could indirectly benefit ACB.TO (+0.1). buyback programs: No mention of buybacks. analyst meetings: Zacks Rank #2 (Buy) (+0.05). Analyst ratings generally receive a low score, but a "Buy" rating is a slight positive. forward P/S valuation: Trading at a forward P/S of 0.55X vs. industry average of 5.60X (+0.2). This indicates a discounted valuation, which is a positive signal. market dynamics: The projected CAGR of 12% for the Canadian cannabis market (2025-2030) (+0.1). This indicates a positive outlook for the market. Negative factors and reasons for low scores: The news contains a lot of backward-looking data (e.g., past year trends, historical sales figures), which receives a low score. The news mentions competition and market dynamics, which introduces uncertainty and limits the positive impact. --- <br> - High Tide (HITI) demonstrates strong retail expansion and a discounted valuation, supported by a growing Canadian cannabis market. The company's consistent store openings, above-average revenue generation, and improving earnings estimates suggest a positive outlook, though investors should monitor market dynamics and competition. <br><br>*** REZUMAT *** - HITI has expanded to 203 Canna Cabana locations in Canada. - Canna Cabana achieved a 12% market share in Feb/Mar. - Average store revenue is 2.3x peers. - Retail sales were $6.8M from April 17-20, 2025. - Canada's legal cannabis market valued at $3.25B in 2024. - Projected CAGR of 12% for the Canadian cannabis market (2025-2030). - Ontario allows operators up to 150 cannabis retail stores. - Village Farms VFF international medical export sales jumped 690% YOY. - Aurora Cannabis ACB international medical cannabis sales surged 85% YOY. - HITI shares up 76.2% in the past year, outperforming industry (3.3%). - HITI trades at a forward P/S of 0.55X vs. industry average of 5.60X. - Loss per share estimate improved 1 cent for 2025 in the last 30 days. - HITI currently holds a Zacks Rank #2 (Buy).   (gemma3:12b-it-q4_K_M on 2025-09-04 12:51:51)</td><td><a href='https://www.theglobeandmail.com/investing/markets/stocks/ACB/pressreleases/34542408/retail-expansion-positions-high-tide-for-long-term-growth/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-28</td><td>0.20</td><td></td><td>product launches</td><td>0.2 local feel              __   ACB.TO __    -> i:0.2<-                      <br><br>FEELING: total score 0.2 Reasoning: The news highlights "potential explosive growth" contingent on "product approval." This falls under the "FDA or Canada Health decisions" event. A potential approval would be a +0.4 event. However, the phrasing "potential" and the need to "monitor regulatory developments closely" introduces significant uncertainty. Therefore, I'm assigning a slightly reduced score of +0.2 to reflect the positive potential tempered by regulatory risk. The rest of the news is promotional and backward-looking, so it receives a very low score. --- <br> - The news indicates potential for significant growth for BioCannabis firm contingent on product approval. Investors should monitor regulatory developments closely. <br><br>*** REZUMAT *** - BioCannabis firm faces potential explosive growth. - Growth dependent on product approval. - News source: Yahoo Finance. - Focus on regulatory approval timeline.   (gemma3:12b-it-q4_K_M on 2025-09-05 04:00:11)</td><td><a href='https://ca.finance.yahoo.com/news/biocannabis-firm-could-explode-product-193000952.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-27</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Individual contributor breakdown: quarterly or annual results: The reported narrower loss and significant revenue growth (176%) aligns with a positive surprise, scoring +0.3. guidance updates: Projected revenue growth of 34% p.a. for the next 2 years, significantly outpacing the Canadian pharmaceutical industry (11% growth), is a positive revision, scoring +0.2. shares down 18% in the last week: This negative price action suggests investor concern, offsetting some of the positive news, scoring -0.1. Rationale: The news highlights strong revenue growth and positive future projections, which are key drivers for a stock's value. The significant outperformance compared to the industry is a particularly positive signal. However, the recent share price decline indicates potential investor concerns or a lack of full confidence in the company's ability to sustain this growth. --- <br> - TRUBAR reported a narrower loss and significant revenue growth (176%) in Q2 2025. Future revenue growth is projected to outpace the Canadian pharmaceutical industry. Investors should monitor the identified risks before investing. <br><br>*** REZUMAT *** - TRUBAR Q2 2025: US$0.018 loss per share (vs US$0.088 in 2Q 2024). - Revenue up 176% to US$17.7m (compared to 2Q 2024). - Net loss narrowed 72% to US$1.96m (compared to 2Q 2024). - Projected revenue growth: 34% p.a. for the next 2 years. - Pharmaceutical industry growth forecast: 11% in Canada. - Shares down 18% in the last week.   (gemma3:12b-it-q4_K_M on 2025-08-27 22:23:36)</td><td><a href='https://simplywall.st/stocks/ca/pharmaceuticals-biotech/tsxv-trbr/trubar-shares/news/trubar-second-quarter-2025-earnings-us0018-loss-per-share-vs' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-19</td><td>0.30</td><td></td><td>Regulatory changes</td><td>0.30 GPT4 / 0.35 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Cannabis sector reclassification under Trump presents a significant opportunity. While risks remain, undervalued equities like Tilray and Aurora offer potential for substantial gains if investors act decisively before the policy is finalized. <br><br>*** REZUMAT *** - Trump signals openness to reclassifying cannabis from Schedule I to Schedule III. - Reclassification could unlock institutional capital and ease regulatory friction. - Cannabis was classified as Schedule I since 1970 under Nixon. - Schedule III designation could remove Section 280E tax burden. - AdvisorShares Pure U.S. Cannabis ETF (MSOS) surged 28% on August 11. - Tilray Brands (TLRY) trades at $0.44 with a $0.93 price target. - Aurora Cannabis (ACB) shows 37% revenue growth in Q3 2025. - Canopy Growth (WEED) has an average 12-month price target of C$3.87. - Organigram Holdings (OGI) boosted revenue by 74% year-over-year. - Advanced Flower Capital (AFCG) offers indirect exposure at $4.72. - SAFER Banking Act needed for interstate commerce and full legalization.   <br> <br>-- GPT4: 0.3, Hold, Reclassification potential boosts optimism; watch policy developments closely.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-19 20:43:16)</td><td><a href='https://www.ainvest.com/news/trump-potential-cannabis-reclassification-game-changer-weed-stock-sector-2508/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-18</td><td>0.30</td><td></td><td>Regulatory changes</td><td>0.30 GPT4 / 0.30 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - The podcast highlights Canopy Growth (WEED) and Aurora Cannabis (ACB) as potential beneficiaries of potential US cannabis reclassification. Both stocks have experienced significant declines but present value play opportunities for investors willing to accept risk. <br><br>*** REZUMAT *** - Focus on Canopy Growth (WEED) and Aurora Cannabis (ACB) due to potential US cannabis reclassification. - Canopy Growth last traded at C$1.80, down 80.09% YTD and 99.15% since 2020. - Aurora Cannabis last traded at C$7, down 24.41% YTD and 94.36% since 2020. - Stocks operate in Canada, US, Europe, Australia, and New Zealand. - Podcast available on Spotify, YouTube, iHeartRadio, Podbean, Stockhouse.   <br> <br>-- GPT4: +0.3, Hold, Potential US reclassification may boost ACB sentiment.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-19 00:24:13)</td><td><a href='https://stockhouse.com/news/the-market-online-news/2025/08/18/the-5-minute-investor-podcast-ep-24-cannabis-reclassification-plays' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-08-16</td><td>-0.20</td><td></td><td>quarterly earnings</td><td>-0.2 local feel              __   ACB.TO __    -> i:0.2<-                      <br><br>FEELING: total score -0.2 Reasoning: The news primarily focuses on a Q1 loss and margin contraction. This aligns with the "quarterly or annual results" event, specifically falling below expectations, which warrants a score of -0.2. The cautionary language ("monitor future earnings reports," "before considering further investment") reinforces the negative sentiment. The lack of specific financial details limits the potential for a more significant negative impact. There are no other events triggered by the provided text. --- <br> - Aurora Cannabis reported a Q1 loss due to margin contraction. Investors should monitor future earnings reports for signs of improved profitability and margin stabilization before considering further investment. <br><br>*** REZUMAT *** - Aurora Cannabis stock dropped. - Q1 loss reported due to margin contraction. - Financial details not specified in the provided text.   (gemma3:12b-it-q4_K_M on 2025-08-17 03:19:29)</td><td><a href='https://www.msn.com/en-us/money/economy/aurora-cannabis-drops-as-margin-contraction-drives-q1-loss/ar-AA1K1vY5' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-08-15</td><td>-0.30</td><td></td><td>Strategic partnership/joint venture</td><td>-0.30 GPT4 / 0.30 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: -0.3 --- <br> - High Tide's significant investment (C$43.8M) in Remexian Pharma marks their entry into the German medical cannabis market, capitalizing on its rapid growth. While a previous deal fell through, this move signals renewed commitment and increased competition. <br><br>*** REZUMAT *** - High Tide acquires 51% stake in Remexian Pharma GmbH for C$43.8M. - Deal marks High Tide's first venture into the international cannabis sector. - Germany's Cannabis Act (April 2023) spurred market growth. - Remexian provides national distribution reach in Germany. - Previous deal with Purecan GmbH was cancelled in January. - Germany is a top importer, primarily from Canada, Netherlands, Portugal. - Competition expected to increase in German cannabis wholesale/import.   <br> <br>-- GPT4: -0.3, Hold, Increased competition in Germany may pressure ACB.TO's market share.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-15 22:12:11)</td><td><a href='https://mugglehead.com/high-tide-secures-foothold-in-german-medical-market-after-stalled-january-attempt/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-15</td><td>0.30</td><td></td><td>nan</td><td>0.30 GPT4 / 0.30 local feel              __   ACB.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Aurora Cannabis is demonstrating significant growth in the medical market, with a substantial 93% sales increase. This positive momentum suggests a potential turnaround for investors, but continued monitoring is advised. <br><br>*** REZUMAT *** - ACB reports a 93% sales jump in the medical market. - Significant growth indicates a potential market turnaround. - Focus on medical market strengthens Aurora's position.   <br> <br>-- GPT4: +0.3, Hold, Strong medical sales boost but monitor for sustained growth.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-15 22:13:35)</td><td><a href='https://www.msn.com/en-us/money/other/aurora-cannabis-inc-acb-becomes-medical-market-powerhouse-with-93-sales-jump/ar-AA1JMBnc?ocid=finance-verthp-feeds&apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1' target='_blank'>Link</a></td></tr></table></div></div>
    </div>
    </body>
    </html>
    